Goldman Sachs
ARQT icon

Goldman Sachs’s Arcutis Biotherapeutics ARQT Stock Holding History

Goldman Sachs’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7M Buy
1,668,367
+65,354
+4% +$1.52M ﹤0.01% 1929
2026
Q1 		$37.8M Buy
1,603,013
+26,600
+2% +$679K ﹤0.01% 1808
2025
Q4 		$45.8M Sell
1,576,413
-228,575
-13% -$5.85M 0.01% 1572
2025
Q3 		$34M Sell
1,804,988
-85,258
-5% -$1.34M ﹤0.01% 1753
2025
Q2 		$26.5M Buy
1,890,246
+786,833
+71% +$11M ﹤0.01% 1874
2025
Q1 		$17.3M Sell
1,103,413
-202,754
-16% -$2.86M ﹤0.01% 2159
2024
Q4 		$18.2M Sell
1,306,167
-283,715
-18% -$3.11M ﹤0.01% 2212
2024
Q3 		$14.8M Buy
1,589,882
+782,548
+97% +$7.72M ﹤0.01% 2335
2024
Q2 		$7.51M Buy
807,334
+810
+0.1% +$7.33K ﹤0.01% 2785
2024
Q1 		$7.99M Buy
806,524
+73,522
+10% +$549K ﹤0.01% 2684
2023
Q4 		$2.37M Buy
733,002
+399,992
+120% +$1.09M ﹤0.01% 3786
2023
Q3 		$1.77M Sell
333,010
-361,311
-52% -$3.07M ﹤0.01% 3863
2023
Q2 		$6.62M Buy
694,321
+447,345
+181% +$4.97M ﹤0.01% 2843
2023
Q1 		$2.72M Sell
246,976
-32,689
-12% -$473K ﹤0.01% 3602
2022
Q4 		$4.14M Buy
279,665
+96,368
+53% +$1.68M ﹤0.01% 3335
2022
Q3 		$3.5M Buy
183,297
+87,119
+91% +$1.97M ﹤0.01% 3469
2022
Q2 		$2.05M Buy
96,178
+33,605
+54% +$689K ﹤0.01% 4027
2022
Q1 		$1.21M Buy
62,573
+14,339
+30% +$243K ﹤0.01% 4671
2021
Q4 		$1M Buy
48,234
+7,607
+19% +$151K ﹤0.01% 4838
2021
Q3 		$971K Buy
40,627
+8,868
+28% +$202K ﹤0.01% 4771
2021
Q2 		$866K Buy
31,759
+10,362
+48% +$292K ﹤0.01% 4866
2021
Q1 		$619K Sell
21,397
-203,368
-90% -$6.35M ﹤0.01% 4962
2020
Q4 		$6.32M Buy
224,765
+45,389
+25% +$1.11M ﹤0.01% 2837
2020
Q3 		$5.26M Buy
179,376
+7,462
+4% +$199K ﹤0.01% 2853
2020
Q2 		$5.2M Sell
171,914
-27,716
-14% -$801K ﹤0.01% 2778
2020
Q1 		$5.95M Buy
+199,630
New +$5.36M ﹤0.01% 2503

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs's ARQT Position: Q2 2026 in Review

Goldman Sachs increased its Arcutis Biotherapeutics (ARQT) stake by 4.1% in Q2 2026, buying an estimated $1.52M and bringing the position to 1,668,367 shares worth $43.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

Goldman Sachs first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $45.8M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Goldman Sachs held 1,668,367 shares of Arcutis Biotherapeutics worth $43.7M as of Q2 2026.
  • Goldman Sachs bought 65,354 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.52M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1929 holding.
  • Goldman Sachs first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Goldman Sachs's Arcutis Biotherapeutics position peaked at $45.8M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.